4594 Stock Overview
Engages in the development of cancer immunotherapy drugs in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BrightPath Biotherapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥56.00 |
| 52 Week High | JP¥100.00 |
| 52 Week Low | JP¥41.00 |
| Beta | 0 |
| 11 Month Change | 33.33% |
| 3 Month Change | -6.67% |
| 1 Year Change | -44.00% |
| 33 Year Change | -52.94% |
| 5 Year Change | -81.99% |
| Change since IPO | -86.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4594 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 12.0% | -1.9% | -0.5% |
| 1Y | -44.0% | 16.9% | 10.8% |
Return vs Industry: 4594 underperformed the JP Biotechs industry which returned 16.9% over the past year.
Return vs Market: 4594 underperformed the JP Market which returned 10.8% over the past year.
Price Volatility
| 4594 volatility | |
|---|---|
| 4594 Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4594's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4594's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kenichi Nagai | www.brightpathbio.com |
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.
BrightPath Biotherapeutics Co., Ltd. Fundamentals Summary
| 4594 fundamental statistics | |
|---|---|
| Market cap | JP¥4.64b |
| Earnings (TTM) | -JP¥1.87b |
| Revenue (TTM) | JP¥262.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs 4594 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4594 income statement (TTM) | |
|---|---|
| Revenue | JP¥262.00m |
| Cost of Revenue | JP¥146.00m |
| Gross Profit | JP¥116.00m |
| Other Expenses | JP¥1.99b |
| Earnings | -JP¥1.87b |
Last Reported Earnings
Dec 31, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 4594 perform over the long term?
See historical performance and comparison